Literature DB >> 8648211

Seropositivities to human papillomavirus types 16, 18, or 33 capsids and to Chlamydia trachomatis are markers of sexual behavior.

J Dillner1, I Kallings, C Brihmer, B Sikström, P Koskela, M Lehtinen, J T Schiller, M Sapp, P A Mårdh.   

Abstract

The association of seropositivity to human papillomavirus (HPV) capsids of types 11, 16, 18, or 33 with sexual behavior was investigated. Among 1002 women visiting family planning or youth clinics in Sweden, an age-matched subsample of 274 women stratified according to lifetime number of sex partners was analyzed. The proportion of HPV-16-seropositive subjects increased linearly at approximately 4% per partner (P < .001), from 4% among those with 1 lifetime partner to 35% among those with >5 lifetime partners. Also, HPV-33 and HPV-18 seroprevalences were linearly dependent on the number of partners (P < .001, increase with 4% per partner, and P = .008, increase with approximately 3% per partner, respectively), providing serologic confirmation that the important mode of transmission of HPV-16, -18, or -33 infection in women is sexual. HPV serology appears to be suitable as a marker of sexual behavior in populations.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8648211     DOI: 10.1093/infdis/173.6.1394

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  30 in total

1.  Sexual behaviour and early coitarche in a national sample of 17 year old Swedish girls.

Authors:  K Edgardh
Journal:  Sex Transm Infect       Date:  2000-04       Impact factor: 3.519

2.  Human papillomavirus 6 seropositivity is associated with risk of head and neck squamous cell carcinoma, independent of tobacco and alcohol use.

Authors:  C S Furniss; M D McClean; J F Smith; J Bryan; K M Applebaum; H H Nelson; M R Posner; K T Kelsey
Journal:  Ann Oncol       Date:  2008-12-15       Impact factor: 32.976

Review 3.  Oral sex and the transmission of viral STIs.

Authors:  S Edwards; C Carne
Journal:  Sex Transm Infect       Date:  1998-02       Impact factor: 3.519

Review 4.  Age-specific human papillomavirus antibody and deoxyribonucleic acid prevalence: a global review.

Authors:  Sarah M Tiggelaar; Margaret J Lin; Raphael P Viscidi; Jia Ji; Jennifer S Smith
Journal:  J Adolesc Health       Date:  2012-02       Impact factor: 5.012

Review 5.  Oral Sex and HPV: Population Based Indications.

Authors:  Anupam Mishra; Veerendra Verma
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2012-02-29

6.  Seropositivity against HPV 16 capsids: a better marker of past sexual behaviour than presence of HPV DNA.

Authors:  A O Olsen; J Dillner; K Gjøen; P Magnus
Journal:  Genitourin Med       Date:  1997-04

7.  Prevalence of anti-human papillomavirus type 16, 18, 31, and 58 virus-like particles in women in the general population and in prostitutes.

Authors:  A Touzé; S de Sanjosé; P Coursaget; M R Almirall; V Palacio; C J Meijer; J Kornegay; F X Bosch
Journal:  J Clin Microbiol       Date:  2001-12       Impact factor: 5.948

8.  Differences in history of sexual behavior between patients with oropharyngeal squamous cell carcinoma and patients with squamous cell carcinoma at other head and neck sites.

Authors:  Kristina R Dahlstrom; Guojun Li; Guillermo Tortolero-Luna; Qingyi Wei; Erich M Sturgis
Journal:  Head Neck       Date:  2010-08-24       Impact factor: 3.147

9.  Natural immune responses against eight oncogenic human papillomaviruses in the ASCUS-LSIL Triage Study.

Authors:  Lauren E Wilson; Michael Pawlita; Phillip E Castle; Tim Waterboer; Vikrant Sahasrabuddhe; Patti E Gravitt; Mark Schiffman; Nicolas Wentzensen
Journal:  Int J Cancer       Date:  2013-05-29       Impact factor: 7.396

10.  Polymer-based enzyme-linked immunosorbent assay using human papillomavirus type 16 (HPV16) virus-like particles detects HPV16 clade-specific serologic responses.

Authors:  Yevgeniy Y Studentsov; Gloria Y F Ho; Morgan A Marks; Robert Bierman; Robert D Burk
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.